Trace Technology for Assays of Novel Biomarkers.
The availability of an easily measurable specific marker for diagnosis of a disease is an important but not always reachable objective. Emergency area is an area where decisions must be taken as quick as possible, and sometimes it is not clear if the patient is well enough to be treated as an outpatient or must be hospitalized. During last few years many new biomarkers and techniques for their measurement have been developed, and surely some others will appear. The aim of this report was to present TRACE technology for specific assays such as: copeptin, proadrenomedullin and proatrial natriuretic peptide. Ongoing research is being done to decide in which diseases they might be useful and if they will be needed for diagnosis, prognosis or treatment monitoring. Results are not conclusive yet, but in the future some of these markers could be used in routine laboratory work if their utility is documented by new data.
Hospital Galdakao-Usansolo , Spain.
Edurne
E
Bereciartua
Clin Chem. 2005 Oct;51(10):1823-9
16099941
Clin Chem. 2004 Jan;50(1):234-6
14709661
Clin Chem. 2007 Dec;53(12):2193-201
17951293
J Card Fail. 2007 Feb;13(1):42-9
17339002
Crit Care. 2010;14(3):R106
20529344
Crit Care Med. 2009 Feb;37(2):476-82
19114902
Intensive Care Med. 2008 Nov;34(11):2084-91
18523752
Chin J Traumatol. 2010 Jun 1;13(3):152-7
20515592
J Am Coll Cardiol. 2008 May 13;51(19):1857-64
18466800
J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80
17996563
Clin Chem. 2006 Jan;52(1):112-9
16269513
J Am Coll Cardiol. 2007 Apr 10;49(14):1525-32
17418290